AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany

Mark-Oliver Zahn, Dominik Linck, Christoph Losem, Christian Gessner, Holger Metze, Vincent E Gaillard, Hans Werner Tessen, Mark-Oliver Zahn, Dominik Linck, Christoph Losem, Christian Gessner, Holger Metze, Vincent E Gaillard, Hans Werner Tessen

Abstract

Background: Bevacizumab (Avastin®), a recombinant humanized monoclonal antibody, in combination with platinum-doublet chemotherapy has become a routine treatment for advanced non-small-cell lung cancer (NSCLC). The post-authorization, non-interventional study 'AVAiLABLE' assessed the effectiveness and safety of bevacizumab combined with chemotherapy as first-line treatment.

Methods: Nine hundred and eighty-seven adult patients (mean age 61.5 years, 59.8% male) with non-resectable advanced, metastatic or recurrent, predominantly non-squamous NSCLC were evaluated at 185 sites across Germany. 72.8% of the patients had stage IV disease at start of observation, 90.1% had histologically confirmed adenocarcinoma and 80.8% met the bevacizumab label 'NSCLC other than predominantly squamous cell histology'. According to bevacizumab label, chemotherapy plus bevacizumab was recommended, followed by bevacizumab maintenance therapy. Effectiveness endpoints included response rates and progression-free survival (PFS); safety endpoints comprised adverse drug reactions (ADRs). Patients were followed until progression or intolerable toxicity. Data were evaluated by descriptive statistical methods.

Results: Median PFS was 7.4 months (95% CI: 7.1; 8.4), overall response rate (ORR) 45.6% and disease control rate (DCR) 75%. The majority of patients (72.7%) achieved partial response or stable disease. Complete response was reached by 2.3%. 33.6% of patients experienced an ADR of grade ≥ 3. Bevacizumab-related ADRs of grade ≥ 3 occurred in 5.7% of patients, with the highest incidence for leukopenia, neutropenia, and hypertension.

Conclusions: Results of the non-interventional study 'AVAiLABLE' confirmed the effectiveness and safety of bevacizumab in combination with platinum-based chemotherapy as first-line treatment for advanced NSCLC in accordance with previous studies. No new safety signals were identified. Maintenance therapy with bevacizumab was well tolerated and safe even over extended periods (> 20 cycles).

Trial registration: ClinicalTrials.gov Identifier: NCT02596958; registered on 4 November 2015.

Keywords: Adenocarcinoma; Advanced non-small-cell lung cancer; Bevacizumab (Avastin®) plus chemotherapy; Post-authorization study.

Conflict of interest statement

Ethics approval and consent to participate

The study was evaluated by the Ethics Committee of the Medical Association of Lower Saxony (‘Ärztekammer Niedersachsen’) in Hannover (Germany) prior to start of the observation and performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients gave signed, informed consent to participate in the study.

Consent for publication

Not applicable.

Competing interests

ZMO, LD, LC, GC, MH, THW have nothing to disclose. VEG reports other from Roche Pharma AG during the conduct of the study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Kaplan Meier Analysis of Progression-free Survival (PFS, Analysis Population)

References

    1. Gesundheitsberichterstattung des Bundes: Bericht zum Krebsgeschehen in Deutschland 2016; Berlin, November 2016. . Accessed 06 February 2019.
    1. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al., (editors). SEER Cancer Statistics Review, 1975–2015, National Cancer Institute. Bethesda, MD. , based on November 2017 SEER data submission, posted to the SEER web site, 2018. Accessed 06 February 2019.
    1. Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, et al. 2nd EMSO consensus conference on lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475–1484. doi: 10.1093/annonc/mdu123.
    1. Villaruz LC, Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep. 2015;17(6):26. doi: 10.1007/s11912-015-0448-y.
    1. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v1–27. doi: 10.1093/annonc/mdw326.
    1. Avastin summary of product characteristics. . Accessed 06 February 2019.
    1. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550. doi: 10.1056/NEJMoa061884.
    1. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol. 2009;27:1227–1234. doi: 10.1200/JCO.2007.14.5466.
    1. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713–718. doi: 10.1634/theoncologist.12-6-713.
    1. European Medicines Agency: Assessment Report for Avastin. London, 25 March 2008. . Accessed 06 February 2019.
    1. Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6(8):e22681. doi: 10.1371/journal.pone.0022681.
    1. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomized, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(1):20–30. doi: 10.1093/annonc/mds590.
    1. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S, Jr, Brahmer JR, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(30):3488–3515. doi: 10.1200/JCO.2015.62.1342.
    1. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology – Non-Small Cell Lung Cancer, version 7.2015. . Accessed 06 February 2019.
    1. Lynch TJ, Jr, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, et al. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. J Thorac Oncol. 2014;9(9):1332–1339. doi: 10.1097/JTO.0000000000000257.
    1. EPAR Summary for the Public, EMA/302947/2017. . Accessed 06 February 2019.
    1. Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11(8):733–740. doi: 10.1016/S1470-2045(10)70151-0.
    1. Kosty MP, Wozniak AJ, Jahanzeb M, Leon L, Fish S, Hazard SJ, et al. Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study. Target Oncol. 2015;10(4):509–516. doi: 10.1007/s11523-014-0355-4.
    1. Thatcher N, Garrido Lopez P, Pavlakis N, Laskin J, Dansin E, Griesinger F, et al. Cumulative exposure (EXP) to bevacizumab (BV) maintenance after induction therapy and survival in advanced non-small cell lung cancer (NSCLC): a time-dependent analysis from the SAiL (MO19390) study. Ann Oncol. 2012;23 Suppl 9 (1278P):ix419–20.
    1. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol. 2010;21(9):1804–1809. doi: 10.1093/annonc/mdq020.
    1. Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: results of an exploratory analysis. J Thorac Oncol. 2012;7(11):1707–1712. doi: 10.1097/JTO.0b013e318265b500.
    1. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215–1218. doi: 10.1136/bmj.312.7040.1215.
    1. Borghaei H, Brahmer JR, Horn L, Ready N, Steins MB, Felip E, et al. Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. J Clin Oncol. 2016;34 Suppl; abstr 9025.
    1. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7.
    1. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csöszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi: 10.1056/NEJMoa1606774.
    1. Chen DS, Hurwitz H. Combinations of bevacizumab with Cancer immunotherapy. Cancer J. 2018;24:193–204. doi: 10.1097/PPO.0000000000000327.
    1. Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–1244. doi: 10.1016/S1470-2045(14)70381-X.
    1. Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017;5(5):435–444. doi: 10.1016/S2213-2600(17)30129-7.
    1. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301. doi: 10.1056/NEJMoa1716948.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe